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Cancer is recognized to be a family of gene-based diseases whose causes are to be found in disruptions of basic biologic
processes. An increasingly deep catalogue of canonical networks details the specific molecular interaction of genes and their
products. However, mapping of disease phenotypes to alterations of these networks of interactions is accomplished indirectly
and non-systematically. Here we objectively identify pathways associated with malignancy, staging, and outcome in cancer
through application of an analytic approach that systematically evaluates differences in the activity and consistency of
interactions within canonical biologic processes. Using large collections of publicly accessible genome-wide gene expression,
we identify small, common sets of pathways – Trka Receptor, Apoptosis response to DNA Damage, Ceramide, Telomerase,
CD40L and Calcineurin – whose differences robustly distinguish diverse tumor types from corresponding normal samples,
predict tumor grade, and distinguish phenotypes such as estrogen receptor status and p53 mutation state. Pathways identified
through this analysis perform as well or better than phenotypes used in the original studies in predicting cancer outcome. This
approach provides a means to use genome-wide characterizations to map key biological processes to important clinical
features in disease.
Citation: Efroni S, Schaefer CF, Buetow KH (2007) Identification of Key Processes Underlying Cancer Phenotypes Using Biologic Pathway Analysis. PLoS
ONE 2(5): e425. doi:10.1371/journal.pone.0000425
INTRODUCTION
Biologic phenomena emerge as consequence of the action of genes
and their products in pathways. Diseases arise through alteration
of these complex networks [1–5]. In order to make mechanistic
assertions that supplement current approaches to genome-wide
analysis [6–9], we map canonical biologic pathways to cancer
phenotypes. A total of 2011 Affymetrix GeneChip array hybridi-
zations obtained from 9 different publicly accessible data sources
[10–17] were analyzed. The hybridizations represented 70 differ-
ent tumor types (1348 samples). Additionally 83 different types
of samples of normal histology were included (663 samples).
Expression levels were adjusted using RMA[18]. The definition of
normal used here excludes uninvolved and/or tumor adjacent
samples obtained from individuals with cancer.
The use of pathways as a framework for analysis is not in itself
novel. These include the projection of known cancer genes and
gene expression data onto pathways [19,20]. What distinguishes
the work presented here is the systematic evaluation of the
interaction structure across predefined canonical networks. In
measuring the state of the interaction it combines information
from gene state and network structure. Multiple gene states may
result in a common pathway score. Conversely, pathway scores
may show greater differences than gene signatures.
Approaches to Pathway Analysis
This investigation complements other work utilizing pathway
information.
More specifically, Segal et. al. [6] defined biological modules
and refined them to a set of statistically significant modules. They
were able to use these modules to gain a better perspective on the
different biological processes that are activated and de-activated in
various clinical conditions. We note two main differences between
what we present here and the work in Segal et. al. [6]: first, the
biological modules used in the paper, although highly informative
and useful, are internally defined within the paper. The de-
termination of genes in these modules was derived from the same
data to which they are later applied. The canonical pathways we
use are externally defined independent from the data we analyze,
represent current understanding in the field, and were not derived
ad-hoc. Second, Segal et. al. do not make explicit use of the
interconnections, or the network structure, that exists between
genes that comprise biological modules. The scores for activity and
consistency we present here depend on network structure and
specific relations (such as inhibition and promotion) that are
features of the network information.
Another important approach is that of Rhodes et. al. [21], in
which the human interactome network is used to identify
subnetworks activated in cancer. The approach Rhodes el. al.
use, in contrast to the one presented here, does not attempt to
computationally and algorithmically highlight differences in
phenotypes by building a classifier around measurable network
features. Instead, it generates subnetworks by their association with
sets of genes identified through the over (or under) expression in
each biological phenotype. Rhodes et. al. approach does make use
of the network structure to build the subnetwork, but does not
make further use in observing the co-expression or co-silencing of
sets of genes, as is the case in the work presented here.
Bild et. al. [14] and Glinski et. al. [22] demonstrate that gene
signatures determined by small set of pre-selected canonical
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PLoS ONE | www.plosone.org 1 May 2007 | Issue 5 | e425pathways can distinguish tumor characteristics. In their work, they
start with a limited set of pathways, (e.g. Bild et. al. use 5 pathways)
and show that they differ in different phenotypes. As this approach
starts with a small set of pathways the authors chose to examine, it
does not have the capacity to discover new pathway associations
with phenotypes. Unlike the current work, it does not employ an
objective method to identify set of pathways that can discriminate
phenotypes.
Gene set Enrichment Analyses [23] allows the authors to choose
a set of genes and to determine their relative statistical significance
in a list of genes that separate phenotypes. Gene set enrichment
starts with the premise of individual genes as classifiers. Pathway
membership is measured to assess combined contributions. Again,
the method does not make use of the structure of the network, nor
does it provide a systemic account for the combined knowledge of
pathways to reduce to an optimal set of classifying processes. Since
the method starts with the discrimination of single genes, it can
only build on this statistical inference, and does not account for
any differences that come from the inter-dependency of multiple
gene interactions. For example, if gene A seems to permutate
randomly in the two phenotypes and gene B seems to permutate
randomly in the two phenotypes then each of the genes will score
poorly in a statistical significance test. However, the score defined
by their combined dependence (e.g. (if A then B)) might provide
much greater discrimination.
The method by Tomfohr, et. al. [24] is perhaps the closest to
the one presented here in that it looks at combined groups of genes
and ranks them accordingly. However, Tomfohr, et. al. do not use
the network structure knowledge to obtain scores, but instead
perform Singular Value Decomposition (SVD) to choose a specific
metagene, and define a pathway activity as the expression of that
gene. As such, the result does not utilize the interdependence of
the network as does the work presented above.
METHODS
Evaluating a gene status:
Gene status in evaluating the network interaction is calculated
from the observed data as one of two alternative states: down and
up. To be able to identify whether a gene is in a ‘‘down’’ state or
an ‘‘up’’ state, we look at its (RMA adjusted [18]) expression value
in a sample, compared to the expression values of the same gene in
all other samples. To be able to accommodate a multitude of
probability distributions, we use a gamma distribution as the
template to both the ‘‘down’’ distribution form as well as the ‘‘up’’
distribution, and redefine the problem as a mixture of two gamma
distribution. The suppressed form often follows an exponential
distribution, which is one particular case of a gamma distribution.
The promoted state often follows a form similar to a normal
distribution, which may be approximated by a gamma distribution
of a large mean. Per every probe set measured by the microarray,
we look at the expression distribution and try to fit this distribution
into a mixture of two gamma distributions. We do this by using an
Expectation-Maximization (EM) algorithm, iterating over the data
in a manner that guarantees the increase of likelihood of fitting the
data by the modeled distributions. In the case of two gamma
distributions, we first divide the data into two groups: ‘‘down’’
values and ‘‘up’’ values. The number of genes in the ‘‘up’’ group is
NU and the number of genes in the suppressed group is ND. The
prior probabilities are therefore:
P(Up state)~
Nu
NuzNd
; P(Down state)~
Nd
NuzNd
We assume each group distributes according to a gamma
distribution:
c~f(xja,b)~
1
baC(a)
xa{1e
x
b
The objective of the EM algorithm is to provide us with
maximum-likelihood estimates to the aU,b U values for the
promoted group and to the aD,b D values for the suppressed
group. Additionally, it computes the maximum-likelihood esti-
mates of the mixture coefficients, g1, g2.
We assume that the expression distribution of each gene is
either coming from a mixture of two distributions (one for the
‘‘up’’ case and one for the ‘‘down’’ case) or from a single distribu-
tion (for example, when the gene is ‘‘up’’ in all the samples we
have). We determine the number of underlying distributions (one
or two) using the EM algorithm in combination with a model
selection method, see below.
To find the maximum of the log likelihood, we need to find the
maximum of the auxiliary function Q [25]:
Q(h,h
0)~
X
t
X
i
vt,i(loggi{log(c(xt;ai,bi))
where
vt,i~
g0
i :c(xt;a0
i ,b0
i )
P
j
g0
j c(xt;a0
i ,b0
i )
Here, h is the collection of parameters that define the distribution,
and the superscript 0 designates magnitudes that had been
determined in the previous iteration.
To find maxima, we differentiate Q with respect to the model
parameters, and compare to zero.
LQ
Lbi
~
X
vt,i(aibi{yt)~0
bi~
P
t
vt,iyt
ai
P
t
vt,i
And the coefficients
LQ
Lai ~0[{log(bi):P
t
vt,iz
P
t
vt,i:log(yt){Y(ai)
P
t
vt,i~0
where Y(x) is the psi function
C0(x)
C(x)
.
Using a Lagrange multiplier to incorporate the constrain
P
i
gi~1,
we have to maximize the target function
L(h)~Q{l(
P
i
gi{1)
with respect to the gi, we derive
LL(h)
Lgi
~
LQ
Lgi
{
L
Lgi
l(
X
i
gi{1)
Pathway Augmentation in Cancer
PLoS ONE | www.plosone.org 2 May 2007 | Issue 5 | e425and obtain
gi~
P
t
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We solve this numerically (using MatlabH) in every iterative step,
until we reach some predefined convergence criterion.
Choosing an optimal number of distributions:
Obviously, the more distributions we take as our basis for the
overall distributions, the better fit we have for the data and the
better the likelihood will be. Consider, for example, as many
distributions as there are data points. That would fit the data
exactly and produce maximal likelihood. To overcome this, and to
be able to choose an optimal number, we compare models with
different number of distributions using the Bayesian Information
Criterion (BIC)[26], computed as
BIC ~ log(likelihood){
1
2
(no:offreevariables):
log(no:ofobservations)
This cost function compensates for the additional increase in com-
plexity. The statistical model chosen is the one with the largest
BIC.
Calculate p(Upjx)
p(x,Up)~p(Up)   f(xjaU,bU)~
NU
N
1
bUC(aU)
xaU{1e
{ x
bU
And similarly:
p(x,Down)~p(Down)   f(xjaD,bD)~
ND
N
1
bDC(aD)
xaD{1e
{ x
bD
But we need the probability of being in the ‘‘promoted’’ state for
a specific expression value:
p(Upjx)~
p(x,Up)
p(x)
And since
p(x)~p(x,Up)zp(x,Down)
we can obtain the needed values by:
p(Upjx)~
NU
N
1
bUC(aU)xaU{1e
{ x
bU
NU
N
1
bUC(aU)xaU{1e
{ x
bUz ND
N
1
bDC(aD)xaD{1e
{ x
bD
For example, the expression of the gene CDKN1A in the dataset
[13] (a collection of 698 tumor samples) follows this distribution
(see Figure 1):
The two distinct distributions (Down and Up) are evident and the
algorithm gives the parameters for the two gamma distributions.
Pathway activity and pathway consistency
1. Pathway consistency score: To determine the pathway
consistency score of a given signaling pathway in a sample,
we follow these steps:
a. Every pathway is a collection of interactions. Input genes
and output genes define each interaction. For each
interaction in the pathway, we first look at the input genes
and determine, for each such gene, the probability of being
in a ‘‘down’’ or ‘‘up’’ state (see ‘‘gene state’’ above)
b. We then determine the probability of the materialization
of the specific interaction as the joint probability of all
needed components (genes)
c. Next, we look at the molecular output of the interaction.
Usually, this output is a list of genes, for which we
establish the probability of being in a ‘‘down’’ or ‘‘up’’
state (see ‘‘gene state’’ above)
d. Next, we calculate the likelihood of the output gene(s)
being in one of the two states, under the given probability
of the interaction (calculated in (b))
e. Lastly, to obtain the pathway consistency score, we
calculate the consistency score for every interaction in the
pathway and average the scores over all the interactions
for which we were able to obtain a score. In Figure 2 we
show an example to calculating the consistency value of
an interaction taken from the pathway ‘‘Signaling events
mediated by Stem cell factor receptor (c-Kit)’’, one of the
NCI-Nature Curated pathways from the Pathway In-
teraction Database (PID)[27]. The specific steps to
calculate consistency in this example are:
i. Establish probabilities to all genes involved in the
interaction. This is done according to the steps
described below (see ‘‘gene state’’ section). The
values we obtain are: P(CREBBP)=0.95;
P(STAT5A)=0.8; P(KIT)=0.7
ii. Calculate the joint probability of an active in-
teraction. Since the input molecules to the in-
teraction are not co-dependent, the joint probability
of the interaction is P(CREBBP)6P(STAT5A)=
0.9560.8=0.76
iii. Calculatethelikelihoodthattheoutputmoleculeisthe
result of the interaction. Since the molecule is solely
dependent on the interaction the likelihood is
Figure 1. An example to the distribution of gene expression and its
resemblance to a mixture of two Gamma distributions. The Up/Down
calls for gene states are based on an expression value classified as
residing in one of the two distinct distributions.
doi:10.1371/journal.pone.0000425.g001
Pathway Augmentation in Cancer
PLoS ONE | www.plosone.org 3 May 2007 | Issue 5 | e425straightforward:
P(activeinteraction)|P(}up}genestate)
zP(non{activeinteraction)
|P(}down}genestate)
~0:76|0:7z(1{0:7)(1{0:76)~0:604
iv. Iterate this computation throughout all interactions
in the pathway. The final score of a pathway is an
average over all interactions.
2. A pathway activity score is the average over activity of
interactions in a pathway. For example, in the previous
example, the interaction activity is 0.76. The main advantage
to calculating pathway activities on top of pathway consis-
tencies is that activities can be calculated even when there is
not enough data to work with the output, as is the case, for
example, when the interaction is based on activating or
modifying molecules without the generation of a novel
molecule as output. In such cases, we can still calculate the
activity, although consistency loses its meaning.
Choosing a minimal set of pathways to classify
phenotype
As we obtain pathway activity and consistency scores for each
pathway, we are able to transform the representation of each bio-
sample from a list of gene expression measurements into a novel
representation, displaying each sample with the collection of
pathway activity and consistency scores. As we use this
representation to distinguish between phenotypes, we wish to find
the minimal set of pathways scores that is able to make the
distinction between phenotypic classes. We use feature selection to
choose an optimal minimal set (see Results). We used different
methods of feature extraction and feature classification [28,29],
including forward selection, backward selection, and floating
search [29]. These methods help in eliminating pathway scores
that do not contribute to making the distinction and highlighting
specific pathways that together achieve an optimal classification
rate.
Pathway metric to predict outcome
Representing each bio-sample using its pathway metrics allows us
to look for patterns in the collection of pathways. By using
clustering algorithms, we see that pathway metric values segregate
samples into groups. If we look at the survival patterns of these
groups, we see that in some cases and for some pathways, the
groups correlate with distinct patterns of survival.
RESULTS
The analysis applied here treats a pathway as a network of genes
whose interactions are logically evaluated in the pathway context
to generate sets of scores. Biologic pathway structure information
was obtained from public sources [27,30,31].
Each pathway is assessed for consistency and activity. A
pathway consistency score is calculated as the average likelihood
of the logical consistency of the collection of interactions given the
calculated states of the genes (see Methods). A pathway activity
score is calculated as the average likelihood of the pathway’s
individual interactions being active given the calculated gene
states. Using basic principles of machine supervised learning
[28,29] a classification algorithm that distinguished each onco-
genic phenotype (e.g. cancer sample verse normal) was generated
and validated. Based on simplicity and comparability of alternative
approaches tested, a Bayesian linear discriminant classifier was
used.
First, a classification algorithm was derived to distinguish
diverse cancer phenotypes from normal phenotype tissues. A
classifier derived from an 1800 sample training set (10-fold
validation) demonstrated 98% success in an independent valida-
tion test set of 211 samples (see Figure 3 and Table 1).
Since linear classifiers turn each of the pathways in the problem
into a variable in the classifier, it is possible through feature
analysis to identify subsets of classifier variables (pathways) that, as
a group, distinguish the phenotypes with high accuracy. Feature
selection was used to identify a set demonstrating the optimal 98%
accuracy of the original classification in the validation sample
analysis. It is composed of the activity scores of six pathways: Trka
Pathway, DNA Damage pathway, Ceramide Pathway, Telomer-
ase Pathway, CD40L Pathway and Calcineurin Pathway.
Cancer is a disease of great phenotypic and molecular hetero-
geneity. Even within a given organ site, phenotypic heterogeneity
Figure 2. An example to calculating the consistency and activity of a single interaction. See Methods for details.
doi:10.1371/journal.pone.0000425.g002
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PLoS ONE | www.plosone.org 4 May 2007 | Issue 5 | e425Figure 3. Classification results of the different classifiers tried. Each panel in the figure corresponds to a different phenotypic difference, according
to panel captions. The horizontal axis in each panel corresponds to the one-dimensional projection calculated by the classification algorithm, that
signifies distance between biological samples, according to the multi dimensional pathway metrics. The vertical axis is a jitter scatter of the samples
to enable a clear view of the separation.
doi:10.1371/journal.pone.0000425.g003
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therefore of additional interest to identify molecular processes that
underlie the phenotypic differences and that predict outcome. We
therefore derived signatures for a variety of subtypes of breast
cancer. These subtypes include: histologic grade (Elston grades 1
vs. 3, or grades 2 vs. 3); P53 status (mutated/wild type); estrogen
receptor positive/negative status (ER+/2); and progesterone
receptor positive/negative status (PgR+/2). The performance of
the classifiers is displayed in Figure 3. In all cases, classifiers with
a small number of pathways (three to six) achieved a high level of
accuracy (83% to 95%). Table 1 shows the different pathway
groups that classify different phenotypes.
We next evaluated the ability of the cancer subtype-specific
signatures to stratify the 236 breast cancer samples by outcome.
Following unsupervised clustering of the cancer samples using the
pathways identified above, Kaplan Meier analyses was performed
(Figure 4). In three cases, a single pathway from the sub-type
signature significantly predicted outcome: the Circadian Rhythms
pathway, from the grade 1/3 signature (P=2.9E-11); the Sonic
Hedgehog pathway, from the grade 2/3 signature (P=4E-8); and
Agrin in Postsynaptic Differentiation, from the P53 signature
(P=4.6E-7). The three pathways in the PgR+/2 signature
separated the samples into two groups with a P value .0001, with
the Bone Remodelling pathway accounting for most of the effect.
Table 1. Pathway names and classes.
..................................................................................................................................................
Classification
Pathway name and metric (A-activity,
C-consistency) Pathway Title
Normal/Tumour separation Trka Receptor (A) Trka Receptor Signaling Pathway
DNA Damage Apoptosis (A) Apoptotic Signaling in Response to DNA Damage
Ceramide (A) Ceramide Signaling Pathway
Telomerase (A) Overview of telomerase RNA component gene hTerc
Transcriptional Regulation
CD40L (A) CD40L Signaling Pathway
Calcineurin (A) Effects of Calcineurin in Keratinocyte Differentiation
Separation of Histological Grades 1/3 in breast
cancer tumour
NGF (A) Nerve Growth Factor Pathway (NGF)
Ras (A) Ras Signaling Pathway
Circadian Rhythms (A) Circadian Rhythms
IL-7 (A) IL-7 Signal Transduction
Separation of Histological Grades 2/3 in breast
cancer
Sonic Hedgehog (A) Sonic Hedgehog Receptor Ptc1 Regulates Cell Cycle
Csk Activation (A) Activation of Csk by cAMP-dependent Protein Kinase Inhibits
Signaling through the T Cell Receptor
ChREBP Regulation (A) ChREBP Regulation by Carbohydrates and cAMP
Trka Receptor (A) Trka Receptor Signaling Pathway
HDAC and CaMK (A) Control of skeletal myogenesis by HDAC and calcium/calmodulin-
dependent kinase (CaMK)
Separation of ER+/ER2 breast cancer samples Th2 activation (A) GATA3 participate in activating the Th2 cytokine genes expression
Lipid Synthesis (A) SREBP Control of Lipid Synthesis
ER modulation (A) Pelp1 Modulation of Estrogen Receptor Activity
LIS1 dependent migration (A) Lissencephaly gene (LIS1) in neuronal migration and development
Erk1/Erk2 MAPK (A) Erk1/Erk2 MAPK Signaling Pathway
Separation of PgR2/PgR+ breast cancer samples Th2 activation (A) GATA3 participate in activating the Th2 cytokine genes expression
Bone remodeling (C) Bone remodeling
Mucosal Healing (A) Trefoil Factors Initiate Mucosal Healing
Separation of P53 mutated/P53 wildtype breast
cancer samples
Cdc25 and chk1 (A) cdc25 and chk1 Regulatory Pathway in Response to DNA damage
Neuronal Survival (A) Role of Erk5 in Neuronal Survival Pathway
Postsynaptic Differentiation (C) Agrin in Postsynaptic Differentiation
Regulation of Splicing (A) Regulation of Splicing through Sam68
T cell activation (A) The Co-Stimulatory Signal During T-cell Activation
ACH Receptor Apoptosis (C) Role of nicotinic acetylcholine receptors in the regulation of
apoptosis
Separation of histological grades 2/3 in colon
cancer
Telomerase (A) Overview of telomerase RNA component gene hTerc
Transcriptional Regulation
NFkB activation (A) NFkB Activation by Nontypeable Hemophilus Influenzae
doi:10.1371/journal.pone.0000425.t001
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PLoS ONE | www.plosone.org 6 May 2007 | Issue 5 | e425In addition, the five pathways in the ER+/2 signature separated
the samples into two groups with a P value of .004, with the
SREBP pathway accounting for most of the effect.
It is important to note that a number of findings in the literature
emerge independently from our pathway analysis of the breast
cancer samples. As the importance of the ER+/2 distinction in
management of breast cancer is well established, we looked at each
of these subgroups separately. It has been observed [32] that the
Trka Pathway (identified in both the generic oncogenic signature
and the grade 2/3 signature) plays a significant role in ER- cases.
Our analysis shows that the generic oncogenic signature separates
the ER- samples into two groups (P=4.6E-9) with the Trka
pathway accounting for most of the effect, high activity of this
pathway correlating with poor prognosis. Likewise, it has been
observed [33,34] that beta-catenin plays a significant role in the
response to tamoxifen, a standard treatment for ER+ disease. To
analyze the nature of the tamoxifen-induced response, we derived
a classifier to distinguish the ER+ cases that had been treated with
tamoxifen from those cases that had not been so treated and then
used the pathways in the resulting signature to cluster the cases by
Figure 4. Examples of the stratification of survival plots and their immediate connections to pathway activity/consistency. (A) (1) Kaplan-Meier
survival plot of breast cancer patients from [15], stratified according to clustering based on pathway activity. Panel (2) in (A) shows the activity score
of the Sonic hedgehog pathway colored according to affiliation with either of the accordingly colored survival curves in (1); (B) The same analyses
done with breast cancer patients from [15], based on the pathway Bone Remodeling (see text for pathway choice). (C) Kaplan Meier survival plots of
lung cancer patient data from [17], stratified according to activity of the Csk pathway and the (D) NFKb pathway. In every panel, the (2) sub-panel
shows the most influential pathway metric out of the group of stratifying pathways. This does not mean that the pathway represented is responsible
for the entire separation into two groups.
doi:10.1371/journal.pone.0000425.g004
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significant (P=1E-13) pathway in predicting outcome.
It has long been suggested that molecular classifications of
cancer may have the capacity to transcend organ or tissue-specific
definitions. More specifically, it has been suggested that molecular
definitions that reflect the universal properties of cell type or
ontology and that underpin a common molecular etiology may
emerge across organ site definitions. To assess whether the
signatures observed above in cancer of breast epithelium may
generalize to other cancers, we examined their capacity to predict
phenotypes in lung and colon cancer. We applied signatures
derived from the breast cancer subtypes to cluster the lung cancer
outcomes (Figure 4). Pathways predicting outcome included the
IL-7 Pathway (P=.002) and the Csk Pathway (P=3E-11). It has
been previously noted that these pathways have been linked with
outcome in lung cancer [35,36]
Lastly, we examined the general oncogenic signature’s capacity
to predict organ-site specific outcome. Interestingly, the signature
pathways separated the 236 breast cancer samples into five
different survival subgroups (P=2E-8) and the 90 lung cancer
samples into two different subgroups (P=5E-17).
DISCUSSION
The above results suggest that using the pathway as the unit of
analysis can augment current individual gene based approaches to
mapping phenotype to underlying molecular process. Objective
identification of processes previously associated with phenotypes
utilizing genome-wide datasets provides partial validation of the
observed results. Newly observed process mappings to phenotypes,
however, clearly require either verification from independent data
sets or experimental confirmation.
The observations made through this analysis are provocative.
Many of these pathways (e.g. apoptosis, telomere maintenance)
have been previously described as universal components of
oncogenesis[2]. Additionally, processes are identified that may
Figure 5. The sub network formed by the six pathways that together create the normal/tumor classifier. The joined pathways color shared nodes.
doi:10.1371/journal.pone.0000425.g005
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tion. Interestingly, novel pathways are also identified as part of the
general oncogenic signature as depicted in the six pathways
collective (e.g. Ceramide and Calcineurin pathways). Recent
interest in Ceramide supports this hypothesis. Ceramide has been
long known to be involved in apoptosis [37–39] and recent work is
looking at the relevancy of ceramide in cancer [40–42] and in
cancer therapy [43], [44]. Similar interest has been developing in
calcineurin. Whereas interest was previously confined to its activity
in immune response, it is now becoming recognized as a pre-
dominant participant in oncogenesis [45,46]. The combination of
this set of pathways may define key processes that are
characteristic of a universal progenitor cell type.
Conversely, the pathway analysis of cancer sub-phenotypes may
also provide novel mechanistic insights that reveal underlying
biology. For example, tamoxifen is effective in treating some cases
of ER+ breast cancer. In these cases, tamoxifen must be affecting
the activity of interaction networks. It is therefore logical to
hypothesize that there will be observable differences in network
activity between those cases where tamoxifen is effective and those
cases where the drug is not effective. Our approach uses pathway
signatures to predict variance in outcome, which is taken as the
measure of drug effectiveness. We speculate that our approach can
reveal those networks that are both differentially activated in
response to treatment with tamoxifen and important to tumor
growth and sustainability.
The approach applied here has parallels to the use of gene maps
for translating phenotypes into the molecular domain. First,
pathway models represent a reproducible framework that can be
tested across studies and extended as further knowledge becomes
available. Also, the pathways and their structure provide a higher
order construct for assessing the role of genes.
Each interaction within a pathway requires the contribution of
multiple gene observations. Each single gene activity level
contributes only in the context of other genes participating in an
interaction within the process network. This is demonstrated by
the observation that we were unable to derive effective classifiers,
directly from the gene-state values alone (for the genes composing
the main six pathways).
It is also interesting that five of the six pathways we use to
classify normal and tumour samples form a single connected
network (Figure 5, the telomerase pathway remains unconnected).
This interconnection may provide novel opportunities for de-
veloping interventions. Knowledge of the connections may suggest
alternative targets that would have multiple pathway effects.
Minimally, it may permit the identification of complexities
associated with target selection prior to intervention design.
It is understood that the probabilistic classification of genes into
alternative states of down and up is a simplification of much
greater complexity patterns of gene behaviour and action.
However, empiric evaluation of the observed data finds that gene
expression patterns commonly can fit one of two alternative
expression level distributions. Moreover, such simplification has
proven valuable in other research domains. For example the
simplification that abstracts digital logic from the underlying
continuous flow of electrons in integrated circuits has enabled the
design of devices of staggeringly complex functionality [47].
It is clear that current knowledge of biologic pathways is
incomplete and imperfect. As such, processes identified are almost
assuredly not the only factors influencing the phenotypes of
interest. Nevertheless, where processes are identified, they serve as
important targets for further investigation. Moreover, the process-
oriented approach allows one to distinguish which components of
the complex networks in which genes participate are differentially
contributing to a phenotype of interest. The combined use of
activity and consistency score permits the discrimination of
processes activated because of the phenotype versus those whose
logic differs between phenotypes. The latter (consistency),
potentially is causally attributable to the phenotype and suggests
candidates that have been altered. However, utilizing gene
expression data, consistency scores can only be calculated for
interactions involving transcription events, limiting their discrim-
inatory power.
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